Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has received feedback from the US FDA following its 'end of review' Type A meeting request with respect to the Sofdra new drug application review. …
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News